新加坡生物科技独角兽Mirxes觅瑞正式纳入港股通，开启北水投资新渠道

Core Insights - Mirxes Holding Limited, a leading cancer early screening company based in Singapore, was listed on the Hong Kong Stock Exchange on May 23, 2025, and quickly gained recognition by being included in the Hang Seng Composite Index and the Hong Kong Stock Connect program within four months [1][2] Company Performance - Since its listing, Mirxes has shown impressive market performance, becoming the first unicorn in Southeast Asia's biotechnology sector with a market capitalization exceeding $1 billion on its listing day [2] - For the first half of 2025, the company reported revenues of $10.5 million, a 9.4% increase compared to the same period in 2024, with gross profit rising to $7.1 million, reflecting a 51.1% year-on-year growth and an increase in gross margin from 49.0% to 67.6% [2] - The company's losses decreased by 36.3% year-on-year to $28.23 million, and cash and cash equivalents rose to $108 million, providing a solid financial foundation for future R&D and commercialization efforts [2] Product and Technology - Mirxes continues to lead the industry with its core competencies, including the world's first approved molecular diagnostic product for gastric cancer screening, GASTROClear™, which has received regulatory approval in Singapore and Thailand, as well as "Breakthrough Medical Device" designation from the FDA in the U.S. [3] - The lung cancer detection product, LUNGClear™, has also performed well, contributing significantly to revenue growth in Southeast Asia and Japan due to its non-invasive and cost-effective nature [3] - The company's miRNA technology has been recognized in China, being included in expert consensus guidelines for early screening and diagnosis of common malignant tumors [3] Market Impact - The inclusion of Mirxes in the Hong Kong Stock Connect program not only broadens its investor base but also serves as a new model for the international development of Asian biotechnology companies [3] - This development highlights Hong Kong's role as a crucial bridge connecting China and the global market, allowing mainland investors to easily participate in the growth of high-quality biotechnology firms [3]